Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

Pα+

Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

  • Dan Crenshaw and Elon Musk Add Fuel to Lykos ‘Dumpster Fire’ Drama
  • ‘They Not Like Us’ — Psychedelic Drug Developers Emphasise Avoidance of Lykos’ Perceived Pitfalls
  • atai Life Sciences
  • Beckley Psytech
  • Compass Pathways
  • MindMed
  • Mini Interview: Joshua Ismin, Psylo
  • Other Stories

Dan Crenshaw and Elon Musk Add Fuel to Lykos ‘Dumpster Fire’ Drama

It’s been another testy week in the admittedly nebulous psychedelic ‘community’, as those in favour of FDA approval of Lykos Therapeutics’ MDMA-assisted therapy for PTSD find their voices elevated by some significant public figures.

Over the weekend, Republican Dan Crenshaw took a break from advertising Endex Fitness, his company that sells ‘the worlds [sic] first integrated modular conceal carry holster pants & shorts’, to take aim at Lykos’ critics.

In a ~2 minute video-assisted tweet, Crenshaw railed against both ICER and Psymposia, arguing that the former “influenced” the FDA Advisory Committee that voted against the intervention. “These technocrats think they know better than scientists”, he wrote, adding that “Their job is to say NO and support the status quo that makes Big Healthcare plenty of money”. “But there’s hope”, Crenshaw’s tweet continued. “These groups aren’t the FDA”, he said, adding that “We must support the science and push past these activist groups.”...

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200
  • Regular Bulletins featuring news, analysis, and research
  • Articles and deep dives across psychedelic drug development, policy, and research
  • Exclusive interviews with researchers, executives, and policymakers
  • Bespoke resources and tools including the Psychedelic Bill Tracker
  • Quarterly video briefings and slide decks

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.